

Addressing Issues of CV Mortality in Clinical Trials With IV Iron: Are We Still Getting a Medical Benefit?

AFFIRM-AHF Trial

Rationale and Design of the AFFIRM-AHF Trial: A Randomised, Double-Blind, Placebo-Controlled Trial Comparing the Effect of Intravenous Ferric Carboxymaltose on Hospitalisations and Mortality in Iron-Deficient Patients Admitted for Acute Heart Failure

Ponikowski P, Kirwan BA, Anker SD, et al. Rationale and design of the AFFIRM-AHF trial: a randomised, double-blind, placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron-deficient patients admitted for acute heart failure. *Eur J Heart Fail*. 2019;21(12):1651-1658. doi:10.1002/ejhf.1710

Link: <https://onlinelibrary.wiley.com/doi/epdf/10.1002/ejhf.1710>

Ferric Carboxymaltose for Iron Deficiency at Discharge After Acute Heart Failure: A Multicentre, Double-Blind, Randomised, Controlled Trial

Ponikowski P, Kirwan BA, Anker SD, et al; AFFIRM-AHF investigators. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. *Lancet*. 2020;396(10266):1895-1904. doi:10.1016/S0140-6736(20)32339-4

Link: [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(20\)32339-4/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32339-4/fulltext)

HEART-FID Trial Design

Randomized Placebo-Controlled Trial of Ferric Carboxymaltose in Heart Failure With Iron Deficiency: Rationale and Design

Mentz RJ, Ambrosy AP, Ezekowitz JA, et al; HEART-FID Trial Investigators. Randomized placebo-controlled trial of ferric carboxymaltose in heart failure with iron deficiency: rationale and design. *Circ Heart Fail*. 2021;14(5):e008100. doi:10.1161/CIRCHEARTFAILURE.120.008100

Link: <https://www.ahajournals.org/doi/reader/10.1161/CIRCHEARTFAILURE.120.008100>

Ferric Carboxymaltose in Patients With Heart Failure and Iron Deficiency

Anker SD, Comin Colet J, Filippatos G, et al; FAIR-HF Trial Investigators. Ferric carboxymaltose in patients with heart failure and iron deficiency. *N Engl J Med*. 2009;361(25):2436-2448. doi:10.1056/NEJMoa0908355

Link: <https://www.nejm.org/doi/pdf/10.1056/NEJMoa0908355?articleTools=true>

Effects of Ferric Carboxymaltose on Hospitalisations and Mortality Rates in Iron-Deficient Heart Failure Patients: An Individual Patient Data Meta-Analysis

Anker SD, Kirwan BA, van Veldhuisen DJ, et al. Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis. *Eur J Heart Fail*. 2018;20(1):125-133. doi:10.1002/ejhf.823

Link: <https://onlinelibrary.wiley.com/doi/epdf/10.1002/ejhf.823>

Iron Deficiency in Heart Failure: An Overview

von Haehling S, Ebner N, Evertz R, Ponikowski P, Anker SD. Iron deficiency in heart failure: an overview. *JACC Heart Fail.* 2019;7(1):36-46. doi:10.1016/j.jchf.2018.07.015

Link:

<https://www.sciencedirect.com/science/article/pii/S2213177918306279/pdf?md5=6ad33f4915a4f8b65605ae0eb0493146&pid=1-s2.0-S2213177918306279-main.pdf>